Compare DHIL & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHIL | EMBC |
|---|---|---|
| Founded | 1990 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 521.7M |
| IPO Year | 1996 | 2021 |
| Metric | DHIL | EMBC |
|---|---|---|
| Price | $171.56 | $8.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 16.8K | ★ 834.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | 3.48% | ★ 6.78% |
| EPS Growth | 14.37 | ★ 20.90 |
| EPS | ★ 17.91 | 0.74 |
| Revenue | ★ $145,201,729.00 | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $9.64 | $11.96 |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $8.47 |
| 52 Week High | $173.70 | $15.55 |
| Indicator | DHIL | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 40.80 |
| Support Level | $171.96 | $8.60 |
| Resistance Level | $173.56 | $9.47 |
| Average True Range (ATR) | 0.66 | 0.38 |
| MACD | -0.13 | 0.06 |
| Stochastic Oscillator | 35.96 | 40.70 |
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.